Imaging of Primary or Recurrent Breast Cancer with 18F-FluorThanatrace Positron Emission Tomography (PET/CT)

Age
99 years or below
Gender
All
participants needed
40
Location
1

Brief description of study

This study recruits participants directly from Penn Medicine clinics, during time of their clinical biopsies. Up to 40 participants with known or suspected primary or metastatic breast cancer who meet eligibility requirements for this study will undergo FTT PET/CT study imaging. Each PET/CT scan will include an injection of up to 12 mCi (approximate range for most studies is anticipated to be 8-12 mCi) of [18F]FTT. Data will be collected to evaluate uptake of [18F]FTT in breast cancer and compare with PARP-1 activity in tissue, when available. If patients are getting neoadjuvant or other systemic therapy, a second optional scan may be performed 1 day to 3 weeks after therapy begins to evaluate whether response correlates with increase in PARP-1 activity.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer, Biopsy
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 832165
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research